These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 26603103)

  • 1. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Wickström M; Dyberg C; Milosevic J; Einvik C; Calero R; Sveinbjörnsson B; Sandén E; Darabi A; Siesjö P; Kool M; Kogner P; Baryawno N; Johnsen JI
    Nat Commun; 2015 Nov; 6():8904. PubMed ID: 26603103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
    BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
    Fruehauf JP; Brem H; Brem S; Sloan A; Barger G; Huang W; Parker R
    Clin Cancer Res; 2006 Aug; 12(15):4523-32. PubMed ID: 16899598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
    Yi GZ; Liu YW; Xiang W; Wang H; Chen ZY; Xie SD; Qi ST
    J Neurol Sci; 2016 Aug; 367():101-6. PubMed ID: 27423571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
    Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
    Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
    Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
    Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
    Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
    Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
    Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
    Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells.
    Li ZY; Huang GD; Chen L; Zhang C; Chen BD; Li QZ; Wang X; Zhang XJ; Li WP
    Mol Med Rep; 2017 Nov; 16(5):5908-5914. PubMed ID: 28849207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.
    Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J
    J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
    Sasai K; Akagi T; Aoyanagi E; Tabu K; Kaneko S; Tanaka S
    Mol Cancer; 2007 Jun; 6():36. PubMed ID: 17547775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
    Zhou Y; Chen L; Ding D; Li Z; Cheng L; You Q; Zhang S
    Sci Rep; 2022 May; 12(1):7773. PubMed ID: 35545654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide and MGMT forever?
    Weller M
    Neuro Oncol; 2010 Mar; 12(3):219-20. PubMed ID: 20167809
    [No Abstract]   [Full Text] [Related]  

  • 18. MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
    Altinoz MA; Elmaci I; Bolukbasi FH; Ekmekci CG; Yenmis G; Sari R; Sav A
    J Chemother; 2017 Aug; 29(4):238-244. PubMed ID: 28436299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cells.
    Yang Z; Wei D; Liu F; Liu J; Wu X; Stevens MFG; Bradshaw TD; Luo Y; Zhang J
    J Cell Biochem; 2018 Jul; 119(7):5350-5358. PubMed ID: 29331023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT in colorectal cancer: a promising component of personalized treatment.
    Zhang L; Zeng J; Zeng Z; Wang F; Wang D; Chen C; Li C; An X; Xu R; Huang P; Ba Y; Li Y
    Tumour Biol; 2016 Aug; 37(8):11443-56. PubMed ID: 27006309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.